LIMNNASDAQ Global Select·USD·Closed·Healthcare · Biotechnology

Liminatus Pharma, Inc. Class A Common Stock

$4.23−$0.17 · −3.86%day vs prior

Mkt Cap · USD

5.68M

P/E · TTM

-0.2

Div Yield · ann

–

52-week

$4.23 – $154.50

at 0% of range

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

Loading chart data...

Signal state